TimesSquare Capital Management’s CG Oncology CGON Stock Holding History

TimesSquare Capital Management’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.2M	Sell	253,708 -172,311	-40%	-$9.76M	0.29%	114
2025 Q4	$17.7M	Sell	426,019 -77,507	-15%	-$3.21M	0.27%	121
2025 Q3	$20.3M	Sell	503,526 -8,675	-2%	-$252K	0.29%	119
2025 Q2	$13.3M	Sell	512,201 -5,057	-1%	-$122K	0.19%	130
2025 Q1	$12.7M	Sell	517,258 -29,646	-5%	-$834K	0.2%	129
2024 Q4	$15.7M	Buy	546,904 +109,835	+25%	+$3.76M	0.23%	126
2024 Q3	$16.5M	Buy	437,069 +94,010	+27%	+$3.3M	0.25%	125
2024 Q2	$10.8M	Buy	343,059 +118,986	+53%	+$4.12M	0.17%	135
2024 Q1	$9.84M	Buy	+224,073	New	+$9.15M	0.14%	143

Other funds holding CGON

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TimesSquare Capital Management's CGON Position: Q1 2026 in Review

TimesSquare Capital Management reduced its CG Oncology (CGON) stake by 40% in Q1 2026, selling an estimated $9.76M and leaving 253,708 shares worth $17.2M. The position accounts for 0.29% of the portfolio, ranked #114.

TimesSquare Capital Management first reported a position in CGON in Q1 2024 and has held it in 9 quarters since. The position peaked at $20.3M in Q3 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

TimesSquare Capital Management held 253,708 shares of CG Oncology worth $17.2M as of Q1 2026.
TimesSquare Capital Management sold 172,311 CG Oncology shares in Q1 2026, an estimated $9.76M.
CG Oncology made up 0.29% of TimesSquare Capital Management's portfolio in Q1 2026, its #114 holding.
TimesSquare Capital Management first reported a position in CG Oncology in Q1 2024 and has held it in 9 quarters since.
TimesSquare Capital Management's CG Oncology position peaked at $20.3M in Q3 2025.
233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on TimesSquare Capital Management's 13F filing for Q1 2026, filed 7 May 2026.